Price T Rowe Associates Inc. MD Raises Position in Repligen Corporation $RGEN

Price T Rowe Associates Inc. MD raised its position in Repligen Corporation (NASDAQ:RGEN) by 6.0% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 7,566,093 shares of the biotechnology company’s stock after acquiring an additional 430,039 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.13% of Repligen worth $962,711,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 3.4% during the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company’s stock valued at $124,727,000 after acquiring an additional 32,665 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after purchasing an additional 594,189 shares in the last quarter. New York State Common Retirement Fund raised its stake in Repligen by 7.6% in the 1st quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company’s stock valued at $79,574,000 after purchasing an additional 43,946 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Repligen by 28.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 580,485 shares of the biotechnology company’s stock valued at $83,556,000 after purchasing an additional 126,913 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its holdings in Repligen by 0.5% in the 1st quarter. Stephens Investment Management Group LLC now owns 539,542 shares of the biotechnology company’s stock valued at $68,651,000 after purchasing an additional 2,741 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were bought at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the transaction, the director directly owned 1,800 shares of the company’s stock, valued at $201,834. This represents a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada upped their target price on shares of Repligen from $193.00 to $204.00 and gave the stock an “outperform” rating in a report on Wednesday, July 30th. Evercore ISI dropped their price objective on shares of Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. JPMorgan Chase & Co. cut their price objective on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research note on Tuesday, July 22nd. Finally, Wells Fargo & Company dropped their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average price target of $169.45.

Repligen Trading Down 1.6%

RGEN opened at $119.65 on Friday. The stock has a market capitalization of $6.73 billion, a PE ratio of -478.58, a P/E/G ratio of 2.24 and a beta of 1.05. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The business’s 50 day moving average price is $121.72 and its 200 day moving average price is $131.78.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period last year, the business earned $0.40 EPS. Repligen’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.